Kinnate Biopharma Inc.

The momentum for this stock is not very good. Kinnate Biopharma Inc. is not a good growth stock. Kinnate Biopharma Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Kinnate Biopharma Inc..

News

XOMA Corporation Announces Closing of Tender Offer

Globe Newswire Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value RightEMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) ( XOMA or the Company...\n more…

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Kinnate Biopharma Inc. by XOMA Corporation

Globe Newswire NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Kinnate Biopharma Inc. ( Kinnate or the...\n more…

Kinnate Biopharma sells exarafenib to Pierre Fabre Laboratories

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

CNW Group - News Releases Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre...\n more…

Kinnate Biopharma sells exarafenib to Pierre Fabre Laboratories

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

Globe Newswire Kinnate has entered into an Asset Purchase Agreement (the APA ) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.The transaction is in furtherance of...\n more…